Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Peters, Solange; Dafni, Urania; Boyer, Michael; De Ruysscher, Dirk; Faivre-Finn, Corinne; Felip, Enriqueta; Garrido, Pilar; Girard, Nicolas; Guckenberger, Matthias; Haanen, John; Le Pechoux, Cecile; Mornex, Francoise; Ozsahin, Mahmut; Paz-Ares, Luis; Planchard, David; Raben, David; Ramalingam, Suresh; Reck, Martin; Smit, Egbert; Stahel, Rolf; Stenzinger, Albrecht; Swanton, Charlie; Vallone, Stefania; Garassino, Marina (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2):161-165.

Peters, Solange; Weder, Walter; Dafni, Urania; Kerr, Keith M; Bubendorf, Lukas; Meldgaard, Peter; O'Byrne, Kenneth J; Wrona, Anna; Vansteenkiste, Johan; Felip, Enriqueta; Marchetti, Antonio; Savic, Spasenija; Lu, Shun; Smit, Egbert; Dingemans, Anne-Marie; Blackhall, Fiona H; Baas, Paul; Camps, Carlos; Rosell, Rafael; Stahel, Rolf A (2014). Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. Journal of Thoracic Oncology, 9(11):1675-1684.

Gautschi, Oliver; Dingemans, Anne-Marie; Crowe, Susanne; Peters, Solange; Roder, Heinrich; Grigorieva, Julia; Roder, Joanna; Zappa, Francesco; Pless, Miklos; Brutsche, Martin; Baty, Florent; Bubendorf, Lukas; Hsu Schmitz, Shu-Fang; Na, Kyung-Jae; Carbone, David; Stahel, Rolf; Smit, Egbert (2013). VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer, 79(1):59-64.

This list was generated on Mon Sep 23 00:53:14 2019 CEST.